Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
126,115
datasets available to search
ShareScore release 0.9.0
Dataset results
126,115 results for “Patients”
Data from: Characterization of gut microbiota composition in hemodialysis patients with normal weight obesity
<p><b>Background:</b> Normal weight obesity (NWO), defined by a normal body mass index (BMI) but increased body fat percentage (BF%), is associated with an increased risk of cardiovascular disease and mortality. NWO is characterized by inflammation and muscle wasting in chronic kidney disease (CKD), but the underlying mechanisms remain largely unknown. Gut microbiota has been implicated in the regulation of host metabolism and may play important roles in the development of NWO in CKD.</p> <p><b>Methods:</b> In this case-control study, we examined the gut microbial diversity and taxonomy in 96 hemodialysis patients with normal weight (BMI <25 kg/m<sup>2</sup> and BF% ≤25% for men or ≤35% for women, n = 32), NWO (BMI <25 kg/m<sup>2</sup> and BF% >25% for men or >35% for women, n = 32), and overweight/obesity (BMI ≥25 kg/m<sup>2</sup>, n = 32), matched for age, gender, and diabetes. BF% was measured using bioimpedance spectroscopy device. Gut microbiota was determined by 16S rRNA sequencing.</p> <p><b>Results:</b> We found that α-diversity was significantly different among the 3 adiposity phenotypes, with NWO being the least diverse. α-diversity was positively correlated with BMI, subjective global assessment score, and physical activity, but negatively correlated with interleukin-6 and tumor necrosis factor-α. Patients with or without NWO were distinguished with respect to principal coordinate analysis of β-diversity. Notably, the relative abundance of butyrate-producing bacteria, such as <i>Faecalibacterium </i><i>prausnitzii</i> and<i> Coprococcus</i>, was markedly reduced in patients with NWO.</p> <p><b>Conclusion:</b> Our findings support associations between gut dysbiosis and a proinflammatory and catabolic state in hemodialysis patients with NWO.</p>
Basic self-disturbances are associated with sense of coherence in patients with psychotic disorders
<p>Background: The <i>Sense of Coherence </i>(SOC)<i> </i>theory<i> </i>gives a possible explanation of how people can experience subjective good health despite severe illness. Basic self-disturbances (BSDs) are subtle non-psychotic disturbances that may destabilize the person's sense of self, identity, corporeality, and the overall 'grip' of the world. </p> <p>Aim: Our objective was to investigate associations between BSDs and SOC in patients with psychotic disorders.</p> <p>Design: This is a cross-sectional study of 56 patients diagnosed with <em><span>psychotic disorders inside and outside the schizophrenia spectrum (35 schizophrenia, 13 bipolar, and eight other psychoses). SOC was measured using Antonovsky's 13-item SOC questionnaire, and BSDs were assessed using the Examination of Anomalous Self-Experience (EASE) manual. Diagnosis, symptoms, and social and occupational performance were assessed using standardized clinical instruments. </span></em></p> <p>Results: We found a statistically significant correlation (r=) between high levels of BSDs and low levels of SOC (r=-0.64/<i>p</i><0.001). This association was not influenced by diagnostics, clinical symptoms or level of functioning in follow-up multivariate analyses.</p> <p>Conclusion: A statistically significant association between BSDs and SOC indicates that the presence and level of self-disturbances may influence the person's ability to experience life as comprehensive, manageable and meaningful. However, the cross-sectional nature of the study precludes conclusions regarding the direction of this association. </p>
Comparing Non-invasive Diabetes Risk Scores for Detecting Patients in Clinical Practice
<p>The Cork and Kerry Diabetes and Heart Disease Study (Phase II – Mitchelstown Cohort) was a single centre study conducted between 2010 and 2011. A random sample was recruited from a large primary care centre in Mitchelstown, County Cork, Ireland. The Livinghealth Clinic serves a population of approximately 20,000 Caucasian-European subjects, with a mix of urban and rural residents. Stratified sampling was employed to recruit equal numbers of men and women from all registered attending patients in the 46–73-year age group. In total, 3,807 potential participants were selected from the practice list. Following the exclusion of duplicates, deaths and subjects incapable of consenting or attending appointment, 3,051 were invited to participate in the study and of these, 2,047 (49% male) completed the questionnaire and physical examination components of the baseline assessment (response rate: 67%). Individuals with pre-existing cardiovascular disease or T2DM were not excluded from the cohort.</p>
Clinical characteristics of patients hospitalized for ocular chemical injuries in Shanghai from 2012 to 2017
Objective: To summarize the clinical characteristics of patients with ocular chemical injuries and evaluate their potential relationship with the visual outcome by analyzing the medical records of these patients from January 1, 2012, to December 31, 2017. Design: A retrospective case series study. Setting: Jinshan Hospital of Fudan University in Shanghai. Methods: Patient data included age, gender, occupational classification, location of ocular chemical injury, initial and final best-corrected distance visual acuity (BCDVA), intraocular pressure (IOP), nature and chemical phase, distribution and severity of chemical injury, management methods, and complications. All variables were evaluated for their potential relationship with visual outcome. Results: A total of 160 patients were hospitalized with ocular chemical injuries. The majority of the patients were factory workers and arrived at the consultation room less than 24 hours after injury. The most common ocular injury setting, classification of severity, causative chemical, chemical phase, and complications were workplace, grade Ⅱ, unknown and mixed substance, liquid, and elevated IOP, respectively. Initial BCDVA was significantly worse in the solid group than in the liquid group (P = 0.009). The risk factors for poor final BCDVA were identified as older age, poor initial BCDVA, and irrigation 24 hours after injury (P < 0.001, P < 0.001, and P = 0.011, respectively). Conclusion: We elaborate the clinical characteristics and outcomes of patients with ocular chemical injuries in Jinshan District, Shanghai. A comprehensive education program should be established and the use of protective eyewear should be promoted to prevent occupation-related ocular chemical injuries.
Cranial CT Scan, Astrocytoma patient after recent tumor removal surgery
<p>A cranial CT scan from a patient with an astrocytoma brain tumor surgically removed August 19, 2014. Scan taken November 19, 2014. Patient: Steven Keating. Patient age: 26 at time of scan. Open access (CC0) with approval from patient. More information available on patient at www.stevenkeating.info.</p>
MRI cranial slices of astrocytoma patient in 2007 and 2014
<p>MRI cranial slices showing astrocytoma tumor growth between 2007 and 2014. Scans taken at Queen's University (2007) and at Mt. Auburn (2014). Patient was born in 1988, tumor removed surgically in August 2014. Pathology of the tumor classified it as an overall grade 2 tumor with two small areas showing signs of grade 3, with the tumor tissue showing an IHD1 gene mutation. After surgery, proton radiation therapy and chemotherapy followed. Uploaded with patient approval (patient: Steven Keating). More information on patient details available at www.stevenkeating.info</p>
Angiotensin II status and sympathetic activation among hypertensive patients in Uganda: a cross-sectional study
<p>A cross sectional study conducted at Mulago, the national referral hospital. Blood samples were taken to measure angiotensin II, metanephrines, normetanephrines and urine samples for creatinine and sodium. The angiotensin II categories were defined using the Mosby's Diagnostic and Laboratory Test References. 9th ed while the metanephrines and normetanephrine cartegories were defined using the Makerere University Biosafety II Immunology Laboratory reference values.</p>
Accompanying data to "Empowerment or concealed compliance? A review of literature on mobile ICT solutions for patient empowerment"
<p>This file contains the details of the systematic literature review that underlies the article "Empowerment or concealed compliance? A review of literature on mobile ICT solutions for patient empowerment". The article will be published in the proceedings of ACM PETRA 2016. This file contains all the coding tables, and the list of included primary studies.</p>
Effects of the OLC following ARDSnet ventilation in patients with early ARDS
<p>Background: Ventilation with low tidal volume (VT) is well recognized as a protective approach to patients with acute respiratory distress syndrome (ARDS), but the optimal level of positive end-expiratory pressure (PEEP) remains uncertain. This study aims to evaluate two protective ventilatory strategies sequentially applied in patients with early ARDS. Methods: In this prospective cohort study, fifteen patients were ventilated during 24h with positive end-expiratory pressure (PEEP) adjusted according to the ARDSnet low-PEEP table (ARDSnet-24h). During the next 24h, nine patients with PaO2/FIO2 ratio below 350 mmHg were ventilated with PEEP titrated according to the Open Lung Concept protocol (ARDSnet+OLC). In the other six patients, regardless of their PaO2/FIO2 ratio, the ARDSnet remained for a further 24 h (ARDSnet-48h). Ventilatory variables, arterial bloodgas and cytokine were obtained at baseline, 24 and 48h. Additionally, whole-lungcomputed tomography was acquired at 24 and 48h. Results: A sustained improvement in PaO2/FIO2 ratio (P=0.008) with a decrease in collapsed regions (P=0.008) was observed in the ARDSnet+OLC group compared with the ARDSnet-24h group. A reduction in IL-6 in plasma (P<0.02) was observed throughout the protocol in the ARDSnet+OLC group. Compared with the ARDSnet-48h group, the ARDSnet+OLC presented smaller amounts of collapsed areas (P=0.018) without significant differences in hyperinflated regions and in driving and plateau pressures. Conclusions: In this set of patients with early ARDS, mechanical ventilation with an individually tailored PEEP sustained improved pulmonary function with better aeration, without significant increase in hyperinflated areas”</p>
Prostate specific antigen density values among patients with symptomatic prostatic enlargement in Nigeria
<p><strong>Background</strong></p> <p>This study aims to estimate the prostate specific antigen density(PSAD) cut off level for detecting prostate cancer( CAP) in Nigerian men with “grey zone PSA’’(4-10ng/ml) and normal digital rectal examination findings . We addressed this research question: Is the international PSAD cut off of 0.15 ideal for detecting CAP in our symptomatic patients with “grey zone PSA’’?</p> <p><strong> Methods</strong></p> <p>Aim: To estimate the prostate specific antigen density(PSAD) cut off level for detecting prostate cancer( CAP) in Nigerian men with “grey zone PSA’’(4-10ng/ml) and normal digital rectal examination findings .</p> <p>Design: prospective</p> <p>Setting: A tertiary medical center in Enugu Nigeria</p> <p> Participants: Two hundred and fifty four men with either benign prostatic hyperplasia (BPH) or prostate cancer (CAP) were recruited. </p> <p> Intervention: Patients with PSA above 4ng/ml or abnormal digital rectal examination or hypoecoic lesion in the prostate were biopsied.</p> <p>Outcome measures: PSAD and histology report of BPH or CAP</p> <p><strong>Results</strong></p> <p>Ninety seven patients had cancer of the prostate (CAP) while 157 has benign prostatic hyperplasia (BPH). Seventy two patients had their serum PSA value within the range of 4.0 and 10ng/ml . PSAD cut off level to detect CAP was 0.04(sensitivity 95.88 %; specificity 28.7 %).</p> <p> </p> <p><strong>CONCLUSION</strong> </p> <p>The PSAD cut off level generated for Nigerian men in this study is 0.04 which is relatively different from international consensus. This PSAD cut off level has a positive correlation with histology and could detect patients with CAP who have “grey zone PSA’’.</p>
Mean curves for all patients
<p>Results of curves of gray levels against distance for both contrasts as obtained with Image J in MRCP.</p>
Myeloperoxidase can differentiate between sepsis and non-infectious SIRS and predicts mortality in intensive care patients with SIRS.
<p>Dataset of "Myeloperoxidase can differentiate between sepsis and non-infectious SIRS and predicts mortality in intensive care patients with SIRS."</p>
Supplementary material for "Patient portal adoption rates: a systematic literature review and meta-analysis"
<p>The attached file contains the searches used to review the literature and identify papers evaluating usage, usability and influence on decision making of patient portals (Supplementary Table 1).</p> <p>Supplementary Table 2 and Supplementary Table 3 contains references and individual studies characteristics of included studies.</p>
Supplementary material for "Patient portal adoption rates: a systematic literature review and meta-analysis"
<p>The attached file contains the searches used to review the literature and identify papers evaluating usage, usability and influence on decision making of patient portals (Supplementary Table 1).</p> <p>Supplementary Table 2 and Supplementary Table 3 contains references and individual study characteristics of included studies.</p>
Pain Experiences of Patients with Musculoskeletal Pain and Central Sensitization: A comparative Group Delphi Study
<p>Central sensitization (CS) is regarded as an important contributing factor for chronification of musculoskeletal pain (MSP). It is crucial to identify CS, as targeted multimodal treatment may be indicated. The primary objective of this study was therefore to explore pain experience of individuals with MSP+CS in order to gain a better understanding of symptoms in relation to CS from a patient perspective. The secondary objective was to investigate whether pain experiences of patients with MSP+CS differ from those of individuals with neuropathic pain (NP).</p>
ROS-Specific Huntingtin Interactions: IP Optimization in Patient-Derived Cells
<p>Optimization step in the lead up to mass spec identification of ROS-specific huntingtin protein-protein interactions.</p>
miRNA counts identified by RNA seq in the caudate nucleus of patients neuropathologically diagnosed with late-onset Alzheimer's disease (non-carriers and carriers of intermediate expansions in the HTT gene) and healthy subjects.
<p>These data include the raw miRNA counts identified by RNA-seq in <em>post mortem</em> caudate nucleus samples. Samples with identifier <strong>A</strong> belong to patients with a neuropathological diagnosis of late-onset Alzheimer's disease. Group <strong>B</strong> samples belong to patients with the same neuropathological diagnosis, but carrying CAG expansions in the intermediate range (27-35 CAG) in the <em>HTT</em> gene. Finally, group <strong>C </strong>samples belong to healthy subjects without neuropathological diagnosis. </p> <p> </p>
Study protocol and data dictionary: Effectiveness of a GP delivered medication review in reducing polypharmacy and potentially inappropriate prescribing in older patients with multimorbidity in Irish primary care: a cluster randomised controlled trial (SPPiRE study)
<p><strong>Methods</strong></p> <p><strong>Study design and participants</strong></p> <p>The methods for the SPPiRE cluster RCT have been described in the trial protocol (21). This study is reported in line with the CONSORT 2010 cluster RCT checklist (22), see Appendix 1, and was approved by the Irish College of General Practitioners Research Ethics Committee. In brief, SPPiRE was a pragmatic two arm cluster RCT, with the intervention delivered to GP clusters and analysis of outcomes at the patient level. Information about the trial was publicised through a variety of GP research, teaching and training networks throughout Ireland. Eligible practices expressing an interest were formally invited. Practices were eligible to participate if they had at least 300 registered patients aged ≥65 years (based on the need to identify a sufficient number of eligible participants) and used either of the two Irish GP practice management systems (PMS) with over 80% national cover; this enabled use of a SPPiRE patient finder tool which was developed and embedded into these systems. Practices were excluded if they were currently involved in a medication management or prescribing trial or if they were unable to recruit at least five participants.</p> <p>Eligible patients were aged ≥65 years and prescribed ≥15 repeat medicines. A repeat medicine was defined as any unique item with a World Health Organisation Anatomical Therapeutic Chemical code on the patient’s current repeat prescription. Patients were excluded if they had been recruited into a practice that was unable to recruit at least four other participants, they were judged by their GP as unable to give informed consent or they were unable to attend the practice for a face to face medication review, (e.g. nursing home residents and house bound patients). Recruited GPs ran the SPPiRE patient finder tool and screened the generated list to ensure only eligible patients were invited. Practices who identified more than 40 eligible patients were supported in selecting a random sample of 30 patients to invite. All recruited practices and patients gave fully informed consent and baseline data was collected prior to practice allocation, to reduce the likelihood of selection bias.</p> <p><strong>Randomisation and masking</strong></p> <p>Recruited practices were allocated to intervention or control groups by minimisation using Minimpy software (23) by the trial statistician (FB) who had no knowledge of participating practices. Minimisation variables included practice size (number of GP sessions per week, 0-14, 14-28 and 28 or more) and location (urban, rural or mixed). Considering the nature of the intervention, it was not possible to blind GPs or patients to the intervention, however to reduce the risk of detection bias the two primary outcome measures; the number of repeat medicines and whether a PIP was present were assessed by an independent blinded pharmacist (MF).</p> <p><strong>Procedures</strong></p> <p>Intervention GPs received unique login details to the SPPiRE website where they had access to five training videos and a template for performing the SPPiRE medication review. The training videos provided background information on multimorbidity and polypharmacy, PIP, eliciting patient treatment priorities and conducting a brown bag medication review. GPs were instructed to book a double appointment and to ask their patients to bring all their medicines in to the medication review visit with them. The SPPiRE medication review process had two main components; gather and record information and then to discuss and agree changes with their patient based on the recorded information, with a focus on deprescribing medicines that were potentially inappropriate, figure 1. The website provided suggested treatment alternatives for identified PIP but all treatment decisions were ultimately at the discretion of the individual GP, based on their clinical judgement and their patients’ individual priorities.</p> <p>Control GPs delivered usual care during the six to twelve month study period. At the time of intervention delivery there was no structured chronic disease management programme in Irish primary care and many patients with multimorbidity attended multiple hospital specialists. In Ireland, the majority of people aged ≥70 years of age have access to free GP visits and medicines with some prescription charge co-payments. In the 65 – 69 year old age category a lower proportion have access to both free GP visits and prescription medicines. Access to specialists and diagnostics in secondary care is free for the entire population.</p> <p><strong>Outcomes</strong></p> <p>The two primary outcomes were the number of repeat medicines and the proportion of patients with any PIP, from a list of 34 pre-specified indicators (see Appendix 2). A series of secondary prescribing related outcome measure were pre-specified to allow a more in depth analysis of the effect of the intervention on prescribing. These were:</p> <ul> <li>The number of medicines stopped and started</li> <li>The proportion of patients with a reduction in significant polypharmacy (defined as ≥15 repeat medicines)</li> <li>The number of PIP</li> <li>The proportion of patients with a high risk PIP (see Appendix 2)</li> <li>The proportion of patients with any reduction in PIP</li> </ul> <p>Secondary patient reported outcomes measures were included to capture the effectiveness of the intervention from the patients’ perspective. These were:</p> <ul> <li>Health related Quality of life (EQ5D-5L)(24)</li> <li>Revised Patients' attitudes towards deprescribing (rPATD) (25)</li> <li>Multimorbidity Treatment Burden Questionnaire (MTBQ) (26)</li> </ul> <p>Health care utilisation data was collected to assess the effect of the intervention on health care usage and for the trial’s economic evaluation.</p> <p>Outcomes were collected at baseline and at six months after intervention delivery. Patient reported measures were collected by postal questionnaires. Data for all other measures including prescribed medicines, medical and investigations history and healthcare utilisation were collected by participating GPs and submitted to the study manager (CMC). This was a deviation from the original protocol, which indicated this data would be collected by the research team. This deviation related to changes in data protection and national health research regulations during the study period, which precluded research team access to the patients’ full clinical record.</p> <p><strong>Adverse events</strong></p> <p>Information on adverse events such as mortality, ED presentations and hospital admissions was collected at follow up. Given the deprescribing approach of the intervention a safety protocol for identifying and reporting any suspected adverse drug withdrawal events (ADWEs) was developed. An ADWE is defined as either recurrence of the condition for which the drug was prescribed (e.g. recurrence of angina after stopping a beta blocker) or a physiologic reaction to drug withdrawal (e.g. SSRI withdrawal syndrome) (27, 28). Although discontinuing medicines in older people has been demonstrated to be safe (29), given the paramount importance of the principle of “do no harm” in research ethics a vigorous and detailed method was established to ensure that any potential ADWEs precipitated by deprescribing in a SPPiRE medication review were captured. Intervention GPs were asked to report any possible ADWE following the SPPiRE medication review. The Naranjo ADR probability scale (30) has been adapted in other studies to assess the likelihood a reaction is related to drug withdrawal (27, 28). This tool was further adapted for SPPiRE and used to make an assessment on the causality of the ADWE. To ensure the patient perspective was included, self-reported possible ADWEs were also collected from patient follow up questionnaires. </p> <p> </p> <p><strong>Sample size</strong></p> <p>As outlined in the trial protocol (21), the study was designed with 90% power to detect a 20% reduction in the proportion with PIP and a mean difference of one medicine between intervention and control groups (based on a mean of 17.4 medicines SD (2.6)) and the sample size inflated to incorporate the effects of clustering (using an ICC of 0.025). The sample size was recalculated when it became apparent during early recruitment that it would not be possible to recruit clusters with an average of 15 participants, as was initially planned in the protocol. An average cluster size of eight was anticipated which inflated the original sample size from 30 practices (450 patients) to 50 practices (400 patients).</p> <p><strong>Statistical analysis</strong></p> <p>Descriptive statistics were used to describe baseline characteristics of recruited practices and participants. All analyses were conducted under the intention-to-treat principle and those lost to follow up had their baseline data carried forward. The primary analysis was carried out using multi-level modelling. The first primary outcome measure, number of repeat medications, was assessed using mixed effects Poisson regression with the individual as the unit of analysis and the practice included as the random effect to control for the effects of clustering and results presented using incidence rate ratios (IRR) and 95% confidence intervals (CI). The baseline number of medicines, GP size (number of GP sessions per week) and GP location (urban/rural) were included in the analysis as fixed effects. The second outcome measure, proportion of patients with a PIP, was analysed in a similar manner using mixed effects logistic regression, including PIP at baseline, GP size and location, and results presented using odd ratios (OR) and 95% CIs. A number of pre-specified sensitivity analyses were conducted; complete case analysis, per protocol analysis and including “presence of a repeat prescribing policy” as a covariate. All secondary outcomes were analysed in a similar manner to the primary outcomes, using appropriate mixed effects regression methods (i.e. linear, logistic, Poisson).</p> <p> </p> <p>Note: Version 3 (published 28 April 2025) updates Version 2 by removing Participant GP1P4 following consent withdrawal. This version should be used for all future analyses.</p> <p> </p>
Quality of life among patients with atrial fibrillation
<p><strong><span>Background</span></strong></p> <p><span>Patients with atrial fibrillation (AF) have significantly lower health-related quality of life (HRQoL) compared to the general population and patients with other heart diseases. The research emphasis on the influence of AF symptoms on HRQoL overshadows the role of individual characteristics. To address this gap, this study's purpose was to </span><span>test an incremental predictive model </span><span>for AF-related HRQoL following an adapted HRQoL conceptual model that incorporates both symptoms and individual characteristics.</span></p> <p><strong><span>Methods</span></strong></p> <p><span>Patients attending an AF specialty clinic were invited to complete an online survey. Hierarchical regression analyses were conducted to examine whether individual characteristics (overall mental health, perceived stress, sex, age, AF knowledge, household and recreational physical activity) incremented prediction of HRQoL and AF treatment satisfaction beyond AF symptom recency and overall health. </span></p> <p><strong><span>Results</span></strong></p> <p>Of 196 participants (mean age 65.3 years), 63% were male and 90% were Caucasian. Most reported 'excellent' or 'good' overall and mental health, had high overall AF knowledge scores, had <span>low </span>perceived stress scores, and had high household and recreation physical activity. The mean overall AF Effect On Quality-Of-Life Questionnaire (<span>AFEQT) and AF treatment satisfaction scores were 70.62 and 73.84, respectively. Recency of </span><span>AF symptoms and overall health accounted for 29.6% of the variance in overall HRQoL and 20.2% of the variance in AF treatment satisfaction. Individual characteristics explained an additional 13.6% of the variance in overall HRQoL and 7.6% of the variance in AF treatment satisfaction. Perceived stress and household physical activity were the largest contributors to overall HRQoL, whereas age and AF knowledge made significant contributions to AF treatment satisfaction.</span></p> <p><strong><span>Conclusions</span></strong></p> <p><span>Along with AF symptoms and overall health, individual characteristics are important predictors of HRQoL and AF treatment satisfaction in AF patients. In particular, perceived stress and household physical activity </span><span>could further be targeted as potential areas to improve HRQoL. </span></p>
Gender and age-related differences of ccular biometric parameters in patients undergoing cataract surgery in Bosnia and Herzegovina
<p><strong>Purpose</strong>: To determine the distribution and mutual relationship of ocular biometric parameters, as well as to evaluate gender- and age-related differences in patients undergoing cataract surgery in Bosnia and Herzegovina.</p> <p><strong>Materials and methods</strong>: It was a retrospective cross-sectional study of consecutive patients who underwent cataract surgery between January 2017 and December 2021 in a tertiary care clinic. All biometric measurements were performed using the optical biometer OA-2000 (Tomey, Nagoya, Japan).</p> <p><strong>Results</strong>: The study evaluated 1278 eyes from 1278 consecutive cataract patients. The average age of all included patients was 69.4 ± 9.98 (range 40–96). A total of 672 eyes (52.58%) were from females. The mean axial length (AL), anterior chamber depth (ACD), lens thickness (LT), and mean keratometry were 23.46±1.18mm, 3.17±0.40mm, 4.54±0.48mm, 43.42±1.55D respectively. Corneal astigmatism of ≥1D, >2D and >3D was found in 33.4%, 7.8% and 2.5% patients, respectively. Females were found to have shorter AL (p<0.0001), shallower ACD (p<0.0001) and steeper corneas (p<0.0001). In both genders, AL, ACD and with-the-rule astigmatism showed a decreasing trend (p=0.0001), while keratometry, the average cylinder, and against-the-rule astigmatism showed an increasing trend (p=0.0001) with increasing age. Furthermore, in both genders, there was an increasing trend in ACD (p=0.0001), and a decreasing trend in keratometry (p=0.0001) and LT (p=0.0001) with increasing AL.</p> <p><strong>Conclusions</strong>: This study provides useful reference data on ocular biometry for cataract surgeons in Bosnia and Herzegovina. Female patients tend to have steeper corneas, shorter AL and shallower AC than males, and these differences are independent of age or AL.</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.